FY2024 EPS Estimates for Danaher Increased by Analyst

Danaher Co. (NYSE:DHR) – Analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of Danaher in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the conglomerate will earn $7.52 per share for the year, up from their prior estimate of $7.49. The consensus estimate for Danaher’s current full-year earnings is $7.49 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2024 earnings at $2.18 EPS.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% on a year-over-year basis.

Other research analysts have also issued research reports about the company. Robert W. Baird cut their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. UBS Group cut their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Stifel Nicolaus boosted their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Finally, KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Price Performance

DHR stock opened at $244.18 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company’s 50-day moving average is $234.75 and its 200-day moving average is $253.50. The stock has a market capitalization of $176.36 billion, a PE ratio of 46.60, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83. Danaher has a 1 year low of $225.42 and a 1 year high of $281.70.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Hedge Funds Weigh In On Danaher

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Decker Retirement Planning Inc. purchased a new stake in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in Danaher in the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the third quarter valued at $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.